A STUDY ON DRUG USE PATTERN AND COST IMPACT OF ANTIDIABETIC DRUGS IN TYPE 2 DIABETIC PATIENTS IN A SECONDARY CARE HOSPITAL

Similar documents
Journal of Pharmaceutical and Scientific Innovation

Scholars Research Library

Ramachandran G, Rohith V, Isabella Topno

COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL

A prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

Use of antihypertensive medications in patients with diabetes in Ajman, UAE

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Cost variation analysis of Oral Hypoglycaemic agents available in Indian market: An Economic Perspective

Britni Hebert, MD PGY-1

TREATMENT PATTERN AND GLYCEMIC CONTROL OF ORAL HYPOGLYCAEMIC DRUGS AMONG TYPE II DM PATIENTS IN ERITREA

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

A STUDY ON DRUG UTILIZATION OF ORAL HYPOGLYCEMIC AGENTS IN TYPE-2 DIABETIC PATIENTS

DRUG UTILIZATION PATTERN AND EFFECTIVENESS ANALYSIS IN DIABETES MELLITUS AT A TERTIARY CARE CENTRE IN EASTERN NEPAL

DRUG UTILIZATION PATTERN IN MEDICAL INTENSIVE CARE UNIT (MICU) IN A TERTIARY CARE TEACHING HOSPITAL IN RURAL AREA OF MAHARASHTRA

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Drug Utilization and Evaluation of Cephalosporin s At Tertiary Care Teaching Hospital, Bangalore

Impact of Part D Coverage Gap on Adherence to Diabetes Medications Feng Zeng, Ph.D.

Robert Okwemba, BSPHS, Pharm.D Philadelphia College of Pharmacy

Quantifying Medication Adherence: Practical Challenges and an Approach to Linking Alternative Measures

bulletin Use of medicines by Australians with diabetes CONTENTS Highlights

FACTORS ASSOCIATED WITH HEALTHCARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY

Glycemic Control of Type 2 Diabetes Mellitus

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

Inhaled Corticosteroids and Diabetes Onset

University of Warwick institutional repository:

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)

Multimorbidity in patients with type 2 diabetes mellitus in the Basque Country (Spain)

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

2T his section provides information about Medicare

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Poorly controlled diabetes mellitus the way forward

Medication Adherence Amongst Diabetic Patients in a Tertiary Healthcare Institution in Central Nigeria

SHORT CLINICAL GUIDELINE SCOPE

Type 2 diabetes is a growing worldwide epidemic, with approximately

Annual Notice of Changes for 2014

SULFONYLUREA USE AND RISK OF HIP FRACTURES AMONG ELDERLY MEN AND WOMEN WITH TYPE 2 DIABETES

Social Support, Depression and Treatment Adherence Among Type 2 Diabetes Patients

India Diabetes Industry Research and Forecasts to FY' Shift towards Modern Insulin Delivery Devices

Prescribing for Diabetes. England to

6. MEASURING EFFECTS OVERVIEW CHOOSE APPROPRIATE METRICS

The Impact of the Medicare Prescription Drug Benefit on Beneficiaries with Diabetes

Summary Table of Benefits Select Medicare Supplement Plan

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

A Guide for the Utilization of HIRA National Patient Samples. Logyoung Kim, Jee-Ae Kim, Sanghyun Kim. Health Insurance Review and Assessment Service

Incidence of drug related problems

4. Does your PCT provide structured education programmes for people with type 2 diabetes?

ALL IN THE FAMILY 75 YEARS OF DIABETES TREATMENT OPTIONS FROM GLASS SYRINGES TO SGLT2 INHIBITORS PETER A. KRECKEL, R.PH.

The Evolution of Taiwan National Health Insurance Drug Policy - Review and Analysis

Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population

There seem to be inconsistencies regarding diabetic management in

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Mental Health Referral Practices and Diabetic Management at Community Medical Alliance Clinic (Bell Site) Northeast Community Clinic (NECC)

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

The Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc.

An integrated IT approach to Chronic Disease Management

Gayle Curto, RN, BSN, CDE Clinical Coordinator

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

EXPLORING THE INTERACTION BETWEEN EXERCISE AND MEDICATION FOR CHRONIC DISEASE: CONSIDERATIONS FOR FITNESS PROFESSIONALS

INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT

Preetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, International Journal of Phytopharmacology

Comparative Review of Oral Hypoglycemic Agents in Adults

Diabetes: Medications

NCDs POLICY BRIEF - INDIA

Diabetes is a costly and increasingly common chronic. Persistence Patterns with Oral Hypoglycemic Agents in Type 2 Diabetes ORIGINAL RESEARCH

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Vildagliptin (Galvus) for type 2 diabetes

Management of Diabetes Mellitus among Elderly Men and Women Impact of Intervention Programme

Prescribing for Diabetes in England - An Update: An analysis of volume, expenditure and trends

Medications for Diabetes

Type 2 Diabetes workshop notes

Understanding Diseases and Treatments with Canadian Real-world Evidence

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians

Exenatide (Byetta) for type 2 diabetes

PRESCRIPTION WRITING FOR PATIENTS WITH DIABETES: COMPLIANCE WITH GOOD PRACTICE

Issued and entered this 20 th day of December 2010 by Ken Ross Commissioner ORDER I PROCEDURAL BACKGROUND

Summary ID# Clinical Study Summary: Study F3Z-JE-PV06

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

Are insulin analogs worth their cost in type 2 diabetes?

REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm)

Benefit Summary - A, G, C, E, Y, J and M

Course Curriculum for Master Degree in Clinical Pharmacy

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Original Research Paper

Brief Research Report: Fountain House and Use of Healthcare Resources

Jill Malcolm, Karen Moir

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics

Carnegie Mellon University Policy #02424 Benefits at a Glance Effective Date: January 1, 2014

How To Determine The Prevalence Of Microalbuminuria

Prescribing for Diabetes, England to

Saxagliptin (Onglyza) for type 2 diabetes

2012 Georgia Diabetes Burden Report: An Overview

echat: Screening & intervening for mental health & lifestyle issues

Achieving Quality and Value in Chronic Care Management

Transcription:

WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Sarumathy S et al. Volume 2, Issue 6, 5913-5919. Research Article ISSN 2278 4357 A STUDY ON DRUG USE PATTERN AND COST IMPACT OF ANTIDIABETIC DRUGS IN TYPE 2 DIABETIC PATIENTS IN A SECONDARY CARE HOSPITAL Sarumathy S* 1, Ravichandiran V 1, Mohammed Sulaiman Sait J 1, Manjula Devi K 2 1 Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai-600117, India. 2 Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Tiruchengode, Namakkal-637205, India. Article Received on 18 September 2013, Revised on 21 October 2013, Accepted on 29 November 2013 *Correspondence for Author: * Sarumathy S. Assistant Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai-600117, India. saruprabakar@gmail.com ABSTRACT In this prospective observational study, a total number of 77 diabetes inpatients were selected in a secondary care hospital. The demographic details, disease and treatment data from the patient case sheets were collected in a separate proforma, updated timely and analyzed. The prescribing pattern of antidiabetic drugs and the mean prescription cost were determined. Higher percentage of male patients was affected with diabetes when compared to the female patients. Age group of 50-59 years had a higher prevalence of type 2 diabetes. Hypertension with diabetes was the predominating co morbidity condition. By analyzing the prescriptions 64.65% of drugs were prescribed in generic. 46% of the drugs were prescribed from WHO essential drug list. Premixed insulin mixtures were the highest prescribed medication. Polypharmacy was seen in more number of prescriptions. The average prescription cost was found to be lesser for treating diabetes (hypoglycemic) alone compared to diabetes associated complaints. KEYWORDS: Diabetes, Polypharmacy, Hypertension, Mean Prescription Cost. www.wjpps.com 5913

INTRODUCTION Diabetes is a chronic metabolic disease associated with significant morbidity and mortality [1]. According to the International Diabetes Federation, 61.3 million people in India had diabetes in 2011. That figure is projected to rise to 101.2 million by 2030 [2]. Data regarding drug use pattern in diabetes is lacking in South Asian countries. Diabetic patients are at a higher risk of polypharmacy and more vulnerable to irrational prescription [3]. Several antidiabetic drug utilization reviews have been published from across the world. Drug utilization review (DUR) of antidiabetic medicines in the healthcare setting can facilitate rational drug use in patients with diabetes [3-8]. They provide useful insights into the current prescribing practices and also identify irrational prescribing [9]. Hence we aimed to study the drug use pattern of antidiabetic drugs in a secondary care hospital. The objectives of this study included the collection of demographic details of the diabetic patients, study of the pattern of drug use among the diabetic patients and calculation of mean prescription cost for the diabetic patients. MATERIALS AND METHODS Study design This prospective observational study was carried out at inpatient department of a secondary care hospital at Salem from October 2010 to April 2011. A total number of 77 diabetes patients, who were joined as in-patient in general medicine ward of a secondary care hospital were selected according to the patient selection criteria. The demographic details, disease and treatment data of patients with diabetes mellitus from the case records were collected in specially designed proformas. The datas were updated timely and were analyzed by using graph pad software. The prescription pattern of antidiabetic drugs according to WHO essential drug list [10] and the mean prescription cost was determined. For the feasibility of analysis, the mean prescription cost was calculated for about 5 days out of each case, irrespective of the total number of days they stayed as in-patients in the ward. Patient Selection Diabetic patients older than 18 years of age of both genders were selected. Exclusion criteria included outpatients and inpatients with type 1 diabetes. RESULTS The study comprised of 77 diabetic patients of which 66% were male and 34% were female patients. The demographic details such as age, gender, social habits and family history of www.wjpps.com 5914

diabetes and duration of existence of diabetes were shown in Table 1. Table 1. Demographic details of the diabetic population S.No. Baseline Parameters Number of patients (n=77) Percentage (%) 1. Gender 51( males) 26 (females) 2. Mean Age in Years 56.70 ± 15.08 years 3. Age 50-59 yrs (27) 70-79 yrs (15) 60-69 yrs (11) 40-49 yrs (9) 30-39 yrs (9) 20-29 yrs (3) 80-89 yrs (3) 4. Social Habits Smoker (14) Alcoholic (8) Smoker and alcoholic (12) Tobacco use (4) None (39) 5. Family history of diabetes Present (17) 6. Duration of existence of diabetes Absent (60) 1-6 months (9) 7-12 months (6) 13-18 months (2) 19-23 months (11) 2-3 yrs (6) > 3 yrs (20) None (23) 66% 34% 35% 19% 14% 12% 12% 04% 04% 18 % 10% 16 % 05 % 51 % 22% 78% 12% 08% 02% 14% 08% 26% 30% Table 2. Distribution based on co morbid illness Co-morbid Conditions No. of diabetic Percentage (%) patients (n = 39) Hypertension 20 51% Renal disorders 8 21% Cardiac disorders 6 15% Foot ulcer 3 8% Neurological disorders 2 5% In this study, 39 (51%) diabetic patients were affected with co morbid disease complications, of which 31 (40%) had diabetes alone and 7 (9%) had diabetes with other complications. Hypertension was the highest associated co morbid disease condition (Table 2). www.wjpps.com 5915

Table 3. Prescription details of the Diabetic patients Details of Prescription Number (%) Total number of drugs prescribed 546 The number of analyzed prescription were 77 Average number of drugs per prescription was found to be 7.09 ± 3.48 Number of drugs prescribed from the WHO List 254 (46.52) Number of drugs prescribed by generic name 353 (64.65) Number of injections prescribed 174 (31.87) Total number of times the antidiabetics prescribed 131 (23.99) The prescription details of the type 2 diabetic patients were shown in Table 3. On analyzing the data, prescriptions containing oral hypoglycaemics + insulin (36%) were found to be higher followed by prescriptions containing oral hypoglycaemic agents + antihypertensive drugs (27%), prescriptions containing oral hypoglycaemics alone (20%) and prescriptions containing insulin alone (17%). The average number of drugs per prescription was found to be 7.09±3.48. Table 4 depicts the distribution based on generic and brand drug usage in the analyzed prescription. Table 4. Distribution Based on Generic and Brand usage Prescription item (n=546) No. of Drugs (%) Generic alone (353) 64.65% Brand alone (193) 35.35% Table 5. Drug Use Pattern Of Anti Diabetic Drugs Drug Number of times prescribed (%) Biguanides Metformin 15 (11.5) Sulphonyl ureas Glimepride Glipizide Glibenclamide 2 (1.5) 4 (3) 4 (3) Thiazolidinediones Pioglitazone 11 (8.4) Alpha-glucosidase inhibitors Voglibose Acarbose Combination 7 (5.3) 1 (0.76) www.wjpps.com 5916

Metformin + Glibenclamide 27 (20.6) Insulin Human insulin (short acting) Human insulin (long acting) 20 (15.26) 02 (1.5) Pre-mixed insulin (Human 38 (29) Mixtard) From the drug use pattern of antidiabetic drugs it was found that human mixtard was the highest prescribed drug compared to that of short acting and long acting insulin. In oral hypoglycaemic category, metformin along with glibenclamide combination was the highest prescribed drug followed by metformin alone and pioglitazone (Table 5). Table 6. Calculation of average prescription cost Therapy type Mean Prescription Cost Antidiabetic drugs 65.26 Others Drugs 389.77 The average prescription cost was found to be 65.26 for treating diabetes alone with hypoglycaemics and 389.77 in order to treat diabetic associated complaints (Table 6). DISCUSSION The present study assessed the drug use pattern of antidiabetic drugs in a secondary care hospital. In our study we found that the mean age was 56.70 ±15.08 years in contrast with the other studies [11, 12]. The average number of drugs prescribed was 7. By analyzing the prescriptions it was found that the prescriptions with generic use (64.65%) were found to be more than those in which brand alone preparations (35.35%). The most associated co morbidity along with diabetes was found to be hypertension [13]. Prescriptions containing combination of oral hypoglycaemics and insulin (36%) were higher followed by oral hypoglycaemic agents with antihypertensive drugs (27%). While considering the drug use, it was found that the most prescribed drug in oral hypoglycaemic was metformin followed by pioglitazone and sulphonyl ureas. In combination category, metformin + glibenclamide combination was the highest prescribed combination. In the insulin category it was found that human mixtard was used more frequently when compared to other type of insulin. While considering the cost of the therapy, it was found that cost for treating diabetic associated complications was higher than diabetes alone. Thus metformin alone and metformin www.wjpps.com 5917

combination was the commonly prescribed antidiabetic drug observed in the present study, in line with findings of other studies [3-5]. CONCLUSION From the above studies it may be concluded that the mostly occurring co morbidity with diabetes is hypertension and most frequently used oral hypoglycaemic agent included metformin. Polypharmacy stands as a hazard in diabetic patients. Patient counseling should be mandatory to the diabetic patients in order to screen out the diabetic risk and taking steps to avoid the diabetic complications becoming worse. Further studies with more patient population and longer period were needed to confirm the study results and also to check the influence of patient counseling in improving the quality of life of the diabetic patients. REFERENCES 1. Mayor S, Diabetes affecting nearly 250 million adults in the world. Br Med J, 2006; 333:1191. 2. IDF diabetes atlas, available at http://www.diabetesatlas.org/content/sea-data/. 3. Upadhyay DK, Palaian S, Ravi Shankar P, Mishra P, and Shah AK, Prescribing pattern in diabetic outpatients in a tertiary care teaching hospital in Nepal. Journal of Clinical and Diagnostic Research, 2007; 1(4): 248 255. 4. Sultana G, Kapur P, Aqil M, Alam MS, and Pillai KK, Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. Journal of Clinical Pharmacology and Therapeutics, 2010; 35: 267 277. 5. Yurgin N, Secnik K, and Lage MJ, Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clinical Therapeutics, 2007; 29: 316 325. 6. Chiang CW, Chiu HF, Chen CY, Wu HL, and Yang CY, Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997 2003. Journal of Clinical Pharmacy and Therapeutics, 2006; 31: 73 82. 7. Johnson JA, Pohar SL, and Secnik K, Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Services Research, 2006; 6: 159. 8. Boccuzzi JS, Wogen J, Fox J, Sung CY, Shah BA, and Kim J, Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care, 2004; 24(8): 1411 1415. www.wjpps.com 5918

9. John LJ, Arifulla M, Sreedharan J, Muttappallymyalil J, Das R, John J, and Basha A, Age and gender-based utilization pattern of antidiabetic drugs in Ajman, United Arab Emirates. Malaysian Journal of Pharmaceutical Sciences, 2012; 10(1): 79 85. 10. WHO Model List of Essential Medicines. 16th ed., March 2010, Available at http://www.who.int/medicines/publications/essentialmedicines/en/index.html/. 11. De Pablos-Velasco PL, Martinez-Martin FJ, Molero R, Fodríguez-Perez F, Garcia Puente I, and Caballero A, Pattern of prescription of hypoglycemic drugs in Gran Canaria (Canary Islands, Spain) and estimation of the prevalence of diabetes mellitus. Diabetes & Metabolism, 2005; 31(5): 457-462. 12. Van den Brink G, Schwartzenberg RR, Hoeve LJ, Porsius AJ, and Hoeve LL, The use of hypoglycemic and cardiovascular drugs in 582 patients with diabetes mellitus. Description and quality assessment. Pharmacy World & Science, 1993; 15(3):128-131. 13. Sandozi T and Emani VK, Survey of prescription pattern of anti-hypertensive drugs in hypertensives & hypertension associated diabetics. International Journal of Pharma and Bio Sciences, Oct- Dec 2010; 1(4):23-26. www.wjpps.com 5919